Abstract: A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.
Type:
Grant
Filed:
March 22, 1999
Date of Patent:
September 25, 2001
Assignee:
The Biomembrane Institute
Inventors:
Steven B. Levery, Sen-itiroh Hakomori, Mark R Stroud
Abstract: An unbranched polylactosamine comprising at least 6 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except for solely at the penultimate N-acetylglucosamine residue.
Type:
Grant
Filed:
July 29, 1996
Date of Patent:
October 17, 2000
Assignees:
The Biomembrane Institute, Seikagaku Corporation
Inventors:
Kazuko Handa, Mary Ellen K. Salyan, Mark R. Stroud, Sen-itiroh Hakomori
Abstract: A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
October 10, 2000
Assignees:
The Regents of the University of Washington, The Biomembrane Institute
Inventors:
Ann Stapleton, Edward Nudelman, Sen-itiroh Hakomori, Walter E. Stamm, Mark Stroud
Abstract: A variety of compounds are provided which are usefdl as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.
Type:
Grant
Filed:
December 29, 1993
Date of Patent:
July 4, 2000
Assignee:
The Biomembrane Institute
Inventors:
Steven B. Levery, Sen-itiroh Hakomori, Mark R. Stroud
Abstract: The invention relates to antibodies that specifically bind a myelorollin comprising an unbranched polylactosamine comprising at least 10 monosaccharides and having terminal .alpha.2.fwdarw.3 sialylation and internal .alpha.1.fwdarw.3 fucosylation at various N-acetylglucosamine residues except the penultimate N-acetylglucosamine residue. The invention also relates to a method of using such antibodies to inhibit E-selectin-dependent rolling of a cell on another cell, wherein one of the cells expresses a myelorollin that binds the antibodies.
Type:
Grant
Filed:
April 22, 1996
Date of Patent:
March 2, 1999
Assignees:
The Biomembrane Institute, Seikagaku Corporation
Inventors:
Kazuko Handa, Mary Ellen K. Salyan, Mark R. Stroud, Sen-itiroh Hakomori
Abstract: A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
Type:
Grant
Filed:
December 6, 1994
Date of Patent:
May 5, 1998
Assignee:
The Biomembrane Institute
Inventors:
Thomas J. Kjeldsen, Henrik Clausen, Anil Singhal, Tatsushi Toyokuni, Helio Takahashi, Sen-itiroh Hakomori
Abstract: A vaccine and method to prevent growth and replication of cancer cells that express a core structure of a mucin-type glycoprotein is disclosed. The vaccine comprises: (a) a pharmaceutically effective amount of an antigen comprising a purified mucin-type glycoprotein or a chemically synthesized mucin-type glycoprotein carbohydrate determinant conjugated to a carrier peptide or macromolecule, wherein said mucin-type glycoprotein expresses or carries the core structure of a mucin-type glycoprotein expressed on said cancer cells; and (b) a pharmaceutically acceptable carrier including natural or synthetic adjuvants. The method comprises administering the above-described vaccine to a host. A medicament and method for treating cancer wherein the cancer cells express a core structure of a mucin-type glycoprotein is disclosed.
Type:
Grant
Filed:
March 8, 1995
Date of Patent:
August 26, 1997
Assignee:
The Biomembrane Institute
Inventors:
Thomas J. Kjeldsen, Henrik Clausen, Anil Singhal, Tatsushi Toyokuni, Helio K. Takahashi, Sen-Itiroh Hakomori
Abstract: Compounds and methods are provided for use in monosaccharide analysis. The present invention discloses hydrazino monosaccharide derivatives. Methods for preparing and using hydrazino monosaccharide derivatives for structural analysis of aldose and ketose monosaccharides are also disclosed.
Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
Abstract: A process for preparing difucosyl Y.sub.2 antigen (dimeric Le.sup.x) , said process comprising: (1) preparing a lactonorhexaosylceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the III.sup.3 and V.sup.3 positions through an .alpha.1.fwdarw.3 linkage. A process for preparing Le.sup.y antigen analogues, said process comprising: (1) preparing a lactonorhexaosyl-ceramide backbone or a lactonorhexaosylsaccharide backbone linked to a carrier molecule; and (2) enzymatically fucosylating said backbone at the terminal .beta.-Gal through an .alpha.1.fwdarw.2 linkage; and (3) enzymatically fucosylating said backbone at one or more positions through an .alpha.1.fwdarw.3 linkage, provided that steps (2) and (3) can be conducted simultaneously or in any order.
Type:
Grant
Filed:
May 24, 1991
Date of Patent:
June 6, 1995
Assignee:
The Biomembrane Institute
Inventors:
Edward Nudelman, Khalid K. Sadozai, Henrik Clausen, Sen-itiroh Hakomori, Mark Stroud
Abstract: A method of producing monoclonal antibodies that bind to tumor-associated gangliosides, the method comprising: (1) immunizing a host with tumor cells; (2) boosting the host with a suspension comprising a mixture of tumor cell membrane and at least one purified lactonized tumor-associated ganglioside; (3) boosting the host with an immunogen comprising a lactone of a tumor associated ganglioside adsorbed on or incorporated into a carrier; (4) fusing immunized cells from the host with myeloma cells to form hybridoma cells; (5) selecting hybridoma cells that produce antibody that binds to the ganglioside of step (3); (6) culturing the selected hybridoma cells; and (7) recovering the antibody.
Type:
Grant
Filed:
December 6, 1991
Date of Patent:
May 23, 1995
Assignees:
The Biomembrane Institute, Jichi Medical School
Inventors:
Edward Nudelman, Anil Singhal, Henrik Clausen, Sen-itiroh Hakomori, Kazuo Muroi, Toshio Suda, Hisao Nojiri
Abstract: Methods are provided for the sequential removal of monosaccharides from the reducing end of oligosaccharides. The present invention also discloses the use of such methods for structural determinations of oligosaccharides and to enable new structures to be generated from pre-existing oligosaccharides. In addition, the methods of the present invention may be automated by the incorporation into systems.
Abstract: A method of inhibiting tumor cell chemotactic and/or chemoinvasion motility comprising contacting the tumor cell with an inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting phagokinetic activity of tumor cells and neutrophils comprising contacting the cells with a phagokinetic inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives. A method of inhibiting tumor cell metastasis comprising administering to a host in need of treatment a metastasis inhibitory amount of an agent selected from the group consisting of sphingosine-1-phosphate, derivatives of sphingosine-1-phosphate, and mimetics of the sphingosine-1-phosphate or of the derivatives, and pharmaceutically acceptable salts of the agent.
Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.
Abstract: A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E.
Type:
Grant
Filed:
August 31, 1992
Date of Patent:
December 20, 1994
Assignee:
The Biomembrane Institute
Inventors:
Ann Stapleton, Edward Nudelman, Sen-itiroh Hakomori, Walter E. Stamm
Abstract: The invention relates to a novel compound, compositions and medicaments thereof and a method of inhibiting cell proliferation, platelet aggregation (induced by various factors) and inhibiting malignant phenotypes of tumor cells such as those having a metastatic property, and modulating cell adhesion molecule expression and function using said compound, composition or medicament. N,N,N-trimethylsphingosine shows superior cell proliferation inhibitory and anti-metastatic activity over related compounds.
Type:
Grant
Filed:
June 30, 1993
Date of Patent:
July 19, 1994
Assignee:
The Biomembrane Institute
Inventors:
Satoshi Kimura, Yasuyuki Igarashi, Sen-itiroh Hakomori, Mohammad N. Ahmad, Hirofumi Okoshi, Kazuko Handa
Abstract: The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.
Type:
Grant
Filed:
August 29, 1991
Date of Patent:
July 5, 1994
Assignee:
The Biomembrane Institute
Inventors:
Fumi-ichiro Yamamoto, Thayer White, Sen-itiroh Hakomori, Henrik Clausen